Lu-Fei Shen1, Xiao-Dong Lv1, Wen-Yu Chen2, Qi Yang3, Zhi-Xian Fang1, Wei-Fen Lu1. 1. Department of Respiration, The First Hospital of Jiaxing, No. 1882 South Zhonghuan Road, Jiaxing, 314000, China. 2. Department of Respiration, The First Hospital of Jiaxing, No. 1882 South Zhonghuan Road, Jiaxing, 314000, China. 1984423@163.com. 3. Department of Respiration, The First Hospital of Jiaxing, No. 1882 South Zhonghuan Road, Jiaxing, 314000, China. jiaxing20071083@126.com.
Abstract
BACKGROUND: Randomized controlled trials (RCTs) of roflumilast effect on chronic obstructive pulmonary disease (COPD) have been reported in the last decade. The current meta-analysis was designed to systematically review and perform meta-analysis of the RCTs of roflumilast treatment in COPD. METHODS: Electronic databases including PubMed, EMBASE, Web of Science, and Cochrane clinical trials database were searched to identify RCTs of roflumilast treatment on COPD. The primary outcomes were effect of roflumilast on pre-bronchodilator FEV1, post-bronchodilator FEV1, and exacerbation rate. Secondary outcomes were effect of roflumilast on airway inflammation and adverse effect. RESULTS: A total of 11 RCTs were enrolled into the current analysis. Roflumilast significantly improved both pre-bronchodilator FEV1 (standardized difference in mean ± SD was 0.621 ± 0.161; 95% CI 0.306~0.936, p < 0.001) and post-bronchodilator FEV1 (standardized difference in mean ± SD was 0.563 ± 0.149, 95% CI 0.270~0.855, p < 0.001) compared with placebo. Roflumilast also significantly reduced exacerbation of COPD (standardized difference in mean ± SD 0.099 ± 0.020, 95% CI 0.061~0.138; p < 0.001) and suppressed airway inflammation (standardized difference in mean ± SD 1.354 ± 0.260, 95% CI 0.845~1.862, p < 0.001) compared with placebo. However, roflumilast significantly increased adverse effect such as diarrhea (rate ratio 2.945, 95% CI 2.453~3.536, p < 0.001) and weight loss (rate ratio 3.814, 95% CI 3.091~4.707, p < 0.001) compared with placebo. CONCLUSION: These findings indicated that roflumilast treatment could improve COPD patients' lung function and reduce exacerbation, and that inhibition of airway inflammation by roflumilast might contribute to the beneficial effect of PDE-4 inhibitors on COPD.
BACKGROUND: Randomized controlled trials (RCTs) of roflumilast effect on chronic obstructive pulmonary disease (COPD) have been reported in the last decade. The current meta-analysis was designed to systematically review and perform meta-analysis of the RCTs of roflumilast treatment in COPD. METHODS: Electronic databases including PubMed, EMBASE, Web of Science, and Cochrane clinical trials database were searched to identify RCTs of roflumilast treatment on COPD. The primary outcomes were effect of roflumilast on pre-bronchodilator FEV1, post-bronchodilator FEV1, and exacerbation rate. Secondary outcomes were effect of roflumilast on airway inflammation and adverse effect. RESULTS: A total of 11 RCTs were enrolled into the current analysis. Roflumilast significantly improved both pre-bronchodilator FEV1 (standardized difference in mean ± SD was 0.621 ± 0.161; 95% CI 0.306~0.936, p < 0.001) and post-bronchodilator FEV1 (standardized difference in mean ± SD was 0.563 ± 0.149, 95% CI 0.270~0.855, p < 0.001) compared with placebo. Roflumilast also significantly reduced exacerbation of COPD (standardized difference in mean ± SD 0.099 ± 0.020, 95% CI 0.061~0.138; p < 0.001) and suppressed airway inflammation (standardized difference in mean ± SD 1.354 ± 0.260, 95% CI 0.845~1.862, p < 0.001) compared with placebo. However, roflumilast significantly increased adverse effect such as diarrhea (rate ratio 2.945, 95% CI 2.453~3.536, p < 0.001) and weight loss (rate ratio 3.814, 95% CI 3.091~4.707, p < 0.001) compared with placebo. CONCLUSION: These findings indicated that roflumilast treatment could improve COPDpatients' lung function and reduce exacerbation, and that inhibition of airway inflammation by roflumilast might contribute to the beneficial effect of PDE-4 inhibitors on COPD.
Authors: E D Bateman; K F Rabe; P M A Calverley; U M Goehring; M Brose; D Bredenbröker; L M Fabbri Journal: Eur Respir J Date: 2011-07-07 Impact factor: 16.671
Authors: Fernando J Martinez; Klaus F Rabe; Sanjay Sethi; Emilio Pizzichini; Andrew McIvor; Antonio Anzueto; Vijay K T Alagappan; Shahid Siddiqui; Ludmyla Rekeda; Christopher J Miller; Sofia Zetterstrand; Colin Reisner; Stephen I Rennard Journal: Am J Respir Crit Care Med Date: 2016-09-01 Impact factor: 21.405
Authors: Diana C Grootendorst; Stefanie A Gauw; Renate M Verhoosel; Peter J Sterk; Jeannette J Hospers; Dirk Bredenbröker; Thomas D Bethke; Pieter S Hiemstra; Klaus F Rabe Journal: Thorax Date: 2007-06-15 Impact factor: 9.139
Authors: Peter M A Calverley; Klaus F Rabe; Udo-Michael Goehring; Søren Kristiansen; Leonardo M Fabbri; Fernando J Martinez Journal: Lancet Date: 2009-08-29 Impact factor: 79.321
Authors: Nicola A Hanania; Peter M A Calverley; Mark T Dransfield; Jill P Karpel; Manja Brose; Haiyuan Zhu; Udo-Michael Goehring; Paul Rowe Journal: Respir Med Date: 2013-09-30 Impact factor: 3.415